The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials

Patricia M. Plezia, David S Alberts, Yei Mei Peng, Min Jian Xu, Susan Sayers, Thomas P Davis, Earl A. Surwit, Frank L. Meyskens

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The design and interpretation of chemoprevention trials are challenging tasks. Innovative methodological approaches to these investigations are in initial stages of development. Important pharmacologic issues should be addressed as early as possible in these trials to facilitate the optimal design of large, Phase III, randomized trials. These include determining the optimal dose of the compound and the toxicity profile. Other key areas involve the use of serum concentrations to monitor subject compliance, the evaluation of concentration of the chemopreventive agent in the target tissue, adequate assessment of the drug delivery systems, and the evaluation of the relationship between the dose administered and the serum or tissue concentrations achieved. Whenever possible the investigation of the relationship between serum or tissue concentrations of a chemopreventive agent vs its biologic activity should be determined. Specific examples involving the retinoids and carotenoids are presented.

Original languageEnglish (US)
Pages (from-to)680-687
Number of pages8
JournalPreventive Medicine
Volume18
Issue number5
DOIs
StatePublished - 1989

Fingerprint

Chemoprevention
Pharmacology
Serum
Retinoids
Carotenoids
Drug Delivery Systems

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. / Plezia, Patricia M.; Alberts, David S; Peng, Yei Mei; Xu, Min Jian; Sayers, Susan; Davis, Thomas P; Surwit, Earl A.; Meyskens, Frank L.

In: Preventive Medicine, Vol. 18, No. 5, 1989, p. 680-687.

Research output: Contribution to journalArticle

Plezia, Patricia M. ; Alberts, David S ; Peng, Yei Mei ; Xu, Min Jian ; Sayers, Susan ; Davis, Thomas P ; Surwit, Earl A. ; Meyskens, Frank L. / The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. In: Preventive Medicine. 1989 ; Vol. 18, No. 5. pp. 680-687.
@article{a11aef04a9054e40ba81fe3c7a1e7373,
title = "The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials",
abstract = "The design and interpretation of chemoprevention trials are challenging tasks. Innovative methodological approaches to these investigations are in initial stages of development. Important pharmacologic issues should be addressed as early as possible in these trials to facilitate the optimal design of large, Phase III, randomized trials. These include determining the optimal dose of the compound and the toxicity profile. Other key areas involve the use of serum concentrations to monitor subject compliance, the evaluation of concentration of the chemopreventive agent in the target tissue, adequate assessment of the drug delivery systems, and the evaluation of the relationship between the dose administered and the serum or tissue concentrations achieved. Whenever possible the investigation of the relationship between serum or tissue concentrations of a chemopreventive agent vs its biologic activity should be determined. Specific examples involving the retinoids and carotenoids are presented.",
author = "Plezia, {Patricia M.} and Alberts, {David S} and Peng, {Yei Mei} and Xu, {Min Jian} and Susan Sayers and Davis, {Thomas P} and Surwit, {Earl A.} and Meyskens, {Frank L.}",
year = "1989",
doi = "10.1016/0091-7435(89)90039-X",
language = "English (US)",
volume = "18",
pages = "680--687",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials

AU - Plezia, Patricia M.

AU - Alberts, David S

AU - Peng, Yei Mei

AU - Xu, Min Jian

AU - Sayers, Susan

AU - Davis, Thomas P

AU - Surwit, Earl A.

AU - Meyskens, Frank L.

PY - 1989

Y1 - 1989

N2 - The design and interpretation of chemoprevention trials are challenging tasks. Innovative methodological approaches to these investigations are in initial stages of development. Important pharmacologic issues should be addressed as early as possible in these trials to facilitate the optimal design of large, Phase III, randomized trials. These include determining the optimal dose of the compound and the toxicity profile. Other key areas involve the use of serum concentrations to monitor subject compliance, the evaluation of concentration of the chemopreventive agent in the target tissue, adequate assessment of the drug delivery systems, and the evaluation of the relationship between the dose administered and the serum or tissue concentrations achieved. Whenever possible the investigation of the relationship between serum or tissue concentrations of a chemopreventive agent vs its biologic activity should be determined. Specific examples involving the retinoids and carotenoids are presented.

AB - The design and interpretation of chemoprevention trials are challenging tasks. Innovative methodological approaches to these investigations are in initial stages of development. Important pharmacologic issues should be addressed as early as possible in these trials to facilitate the optimal design of large, Phase III, randomized trials. These include determining the optimal dose of the compound and the toxicity profile. Other key areas involve the use of serum concentrations to monitor subject compliance, the evaluation of concentration of the chemopreventive agent in the target tissue, adequate assessment of the drug delivery systems, and the evaluation of the relationship between the dose administered and the serum or tissue concentrations achieved. Whenever possible the investigation of the relationship between serum or tissue concentrations of a chemopreventive agent vs its biologic activity should be determined. Specific examples involving the retinoids and carotenoids are presented.

UR - http://www.scopus.com/inward/record.url?scp=0024368629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024368629&partnerID=8YFLogxK

U2 - 10.1016/0091-7435(89)90039-X

DO - 10.1016/0091-7435(89)90039-X

M3 - Article

C2 - 2694162

AN - SCOPUS:0024368629

VL - 18

SP - 680

EP - 687

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

IS - 5

ER -